FDA plans to continue using remote regulatory assessments (RRAs) after the public health emergency ends because, although they were used to allow for some level of inspection during lock-downs, the agency believes RRAs would also make better use of inspectors’ time during normal inspections, according to draft guidance published Friday (July 22). They also could be used to complement inspections by regulators from other countries. Although FDA is for now making do with guidance, which isn’t legally binding, Pharmaceutical Research...